Novel nanocomposite with organosilicon or organogermanium polymer, preparation method thereof and anode active material for lithium secondary battery containing the same

본 발명은 신규 유기규소 또는 유기게르마늄 고분자 나노 복합체, 이의 제조 방법 및 이를 포함하는 리튬 이차전지용 음극활물질에 관한 것이다. 본 발명에 따른 신규한 유기규소 또는 유기게르마늄 나노 복합체를 음극활물질로서 사용한 리튬 이차전지는 기존 흑연소재의 전극보다 구조의 큰 스트레스가 없이 7배 이상의 우수한 용량값과 안정된 배터리 특성을 나타내고, Li 원천의 손실 없이 용량 유지가 가능하며, 초기 용량으로 복귀하는 용량 복귀율이 우수하며, 우수한 사이클 수명을 가지므로 종래 흑연소재의 전극을 포함하는 리튬 이차전지를 대체하여 유용하게 쓰일 수 있다.하기 화학식 1 내지 화학식 3 중 어느 하나의 유기규소 또는 유기게르마늄 고분자 표면에, 실리콘 나노입자(Silicon Nano Particle)가 부착된 신규한 유기규소 또는 유기게르마늄 나노 복합체:[화학식 1][이미지]상기 화학식 1에서, n은 1-4이고,[화학식 2][이미지]상기 화학식 2에서, n은 2-3이고,[화학식 3][이미지]상기 화학식 3에서, n은 1-2이다(상기 화학식 1 내지 3에 있어서,R1, R2, R3, R4 및 R5는 각각 독립적으로 C1-C6 직쇄 또는 측쇄 알킬, 또는 페닐이다)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study

Background: This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis. Methods: Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores <=-2.5 at the lumbar spine, total hip, or femoral neck) were randomized (1:1) to receive monthly subcutaneous injections of romosozumab (210 mg; n=34) or placebo (n=33) for 6 months. Results: At month 6, the difference in the least square (LS) mean percent change from baseline in lumbar spine BMD (primary efficacy endpoint) between the romosozumab (9.5%) and placebo (-0.1%) groups was significant (9.6%; 95% confidence interval, 7.6 to 11.5; P<0.001). The difference in the LS mean percent change from baseline was also significant for total hip and femoral neck BMD (secondary efficacy endpoints). After treatment with romosozumab, the percent change from baseline in procollagen type 1 N-terminal propeptide transiently increased at months 1 and 3, while that in C-terminal telopeptide of type 1 collagen showed a sustained decrease. No events of cancer, hypocalcemia, injection site reaction, positively adjudicated atypical femoral fracture or osteonecrosis of the jaw, or positively adjudicated serious cardiovascular adverse events were observed. At month 9, 17.6% and 2.9% of patients in the romosozumab group developed binding and neutralizing antibodies, respectively. Conclusion: Treatment with romosozumab for 6 months was well tolerated and significantly increased lumbar spine, total hip, and femoral neck BMD compared with placebo in Korean postmenopausal women with osteoporosi